Table 1.
Summary of the Final Data Set Used to Model the Relationship of the ACR50 Treatment Effect Between 3 Months and 6 Months
| Name of Drug | Class of Drug | Number of Trials | Number of Arms | Number of Patients | References |
|---|---|---|---|---|---|
| Adalimumab | anti‐TNF | 6 | 20 | 2729 | 14, 15, 16, 17, 18, 19 |
| Certolizumab | anti‐TNF | 5 | 13 | 1977 | 20, 21, 22, 23, 24 |
| Etanercept | anti‐TNF | 6 | 13 | 1553 | 25, 26, 27, 28, 29, 30 |
| Golimumab | anti‐TNF | 3 | 10 | 1308 | 31, 32, 33 |
| Anakinra | anti‐IL‐1 | 1 | 6 | 419 | 34 |
| Tocilizumab (Actemra) | anti‐IL‐6R | 7 | 16 | 4326 | 35, 36, 37, 38, 39, 40, 41 |
| Ocrelizumab | anti‐CD20 | 1 | 4 | 145 | 42 |
| Ofatumumab | anti‐CD20 | 1 | 2 | 260 | 43 |
| Rituximab | anti‐CD20 | 2 | 5 | 1247 | 44, 45 |
| Abatacept | anti‐CD28 | 5 | 12 | 2069 | 46, 47, 48, 49, 50, 51 |
| Fostamatinib | SYK kinase inhibitor | 1 | 3 | 457 | 52 |
| Tofacitinib | JAK kinase inhibitor | 2 | 13 | 840 | 53, 54 |
| (MTX) | (DMARD) | 28 | |||
| TOTAL | 40 | 117 | 17 330 |